Pre-Made Efmarodocokin Alfa Biosimilar, Fusion Protein targeting IL22RA1/IL22R1 fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CRF2-9 for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Efmarodocokin Alfa Biosimilar, Fusion Protein targeting IL22RA1/IL22R1 fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CRF2-9 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Interleukin-22 (IL-22) is produced by various leukocytes, it preferentially targets cells with epithelial origins. IL-22 exerts essential roles in modulating various tissue epithelial functions, such as innate host defense against extracellular pathogens, barrier integrity, regeneration, and wound healing. Therefore, IL-22 is thought to have therapeutic potential in treating diseases associated with infection, tissue injury or chronic tissue damage. Efmarodocokin Alfa is an IL-22 recombinant fusion protein that links the human cytokine IL-22 with the Fc portion of a human immunoglobulin.
| Products Name (INN Index) | Pre-Made Efmarodocokin Alfa Biosimilar, Fusion Protein targeting IL22RA1/IL22R1 fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CRF2-9 |
|---|---|
| INN Name | efmarodocokin alfa |
| Target | IL22RA1 |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – IL22 (interleukin 22, IL-22, ILTIF, IL-TIF) – IGHG4 Fc (Fragment constant) |
| VD LC | Fusion – IL22 (interleukin 22, IL-22, ILTIF, IL-TIF) – IGHG4 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Genentech?Inc. (S.San Francisco CA USA) Company |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL22RA1 |
| Package |
